TDC
FSTX

Thompson Davis & Co’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Thompson Davis & Co’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-325
Closed -$22K – 1140
2017
Q3 		$22K Buy
+325
New +$18.6K 0.04% 459

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $481M AUM 46% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Thompson Davis & Co's FSTX Position: Q4 2017 in Review

Thompson Davis & Co sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2017, closing a stake of 325 shares — an estimated $22K sold.

Thompson Davis & Co first reported a position in FSTX in Q3 2017 and held it in 1 quarter. The position peaked at $22K in Q3 2017. 38 funds tracked by Wall St. Rank hold FSTX as of Q4 2017.

  • Thompson Davis & Co reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 325 F-star Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $22K.
  • Thompson Davis & Co first reported a position in F-star Therapeutics, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Thompson Davis & Co's F-star Therapeutics, Inc. Common Stock position peaked at $22K in Q3 2017.
  • 38 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.